Evidence map›Paper›PMID 38865072›Full record

ArticleInfection2025

Low expression of the CCL5 gene and low serum concentrations of CCL5 in severe invasive group a streptococcal disease.

V Kailankangas, S Katayama, K Gröndahl-Yli-Hannuksela, J Vilhonen, M H Tervaniemi, K Rantakokko-Jalava, T Seiskari, E Lönnqvist, J Kere, J Oksi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

V KailankangasFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland. ville.kaila@pirha.fi.
S KatayamaFolkhälsan Research Center, Helsinki, Finland.
K Gröndahl-Yli-HannukselaInstitute of Biomedicine, University of Turku, Turku, Finland.
J VilhonenDepartment of Infectious Diseases, Turku University Hospital, Turku, Finland.
M H TervaniemiFolkhälsan Research Center, Helsinki, Finland.
K Rantakokko-JalavaInstitute of Biomedicine, University of Turku, Turku, Finland.
T SeiskariDepartment of Clinical Microbiology, Fimlab Laboratories, Tampere, Finland.
E LönnqvistDepartment of Clinical Microbiology, Fimlab Laboratories, Tampere, Finland.
J KereFolkhälsan Research Center, Helsinki, Finland.
J OksiDepartment of Infectious Diseases, Turku University Hospital, Turku, Finland.
J SyrjänenFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
J VuopioInstitute of Biomedicine, University of Turku, Turku, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur objective was to elucidate host dependent factors of disease severity in invasive group A Streptococcal disease (iGAS) using transcriptome profiling of iGAS cases of varying degrees of severity at different timepoints. To our knowledge there are no previous transcriptome studies in iGAS patients.

methodsWe recruited iGAS cases from June 2018 to July 2020. Whole blood samples for transcriptome analysis and serum for biomarker analysis were collected at three timepoints representing the acute (A), the convalescent (B) and the post-infection phase (C). Gene expression was compared against clinical traits and disease course. Serum chemokine ligand 5 (CCL5, an inflammatory cytokine) concentration was also measured.

resultsForty-five patients were enrolled. After disqualifying degraded or impure RNAs we had 34, 31 and 21 subjects at timepoints A, B, and C, respectively. Low expression of the CCL5 gene correlated strongly with severity (death or need for intensive care) at timepoint A (AUC = 0.92), supported by low concentrations of CCL5 in sera.

conclusionsLow gene expression levels and low serum concentration of CCL5 in the early stages of an iGAS infection were associated with a more severe disease course. CCL5 might have potential as a predictor of disease severity. Low expression of genes of cytotoxic immunity, especially CCL5, and corresponding low serum concentrations of CCL5 associated with a severe disease course, i.e. death, or need for intensive care, in early phase of invasive group A Streptococcal disease.

Indexed as

Chemokine CCL5Streptococcal InfectionsStreptococcus pyogenesAdolescentAdultBiomarkersFemaleGene Expression ProfilingHumansMaleMiddle AgedSeverity of Illness IndexYoung AdultBiomarkersCCL5 protein, humanChemokine CCL5Critical careSepsisStreptococcal infectionsStreptococcus group ATranscriptome

Identifiers

PMID38865072
PMCPMC11825563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.